HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45,764 | +19.8% | 1,198 | +13.1% | 0.00% | +100.0% |
| Q2 2023 | $38,198 | +28.4% | 1,059 | +35.9% | 0.00% | 0.0% |
| Q1 2023 | $29,748 | -18.2% | 779 | +21.9% | 0.00% | 0.0% |
| Q4 2022 | $36,358 | +29.8% | 639 | -11.0% | 0.00% | 0.0% |
| Q3 2022 | $28,000 | -12.5% | 718 | -0.6% | 0.00% | 0.0% |
| Q2 2022 | $32,000 | +220.0% | 722 | +188.8% | 0.00% | 0.0% |
| Q1 2022 | $10,000 | -60.0% | 250 | -62.3% | 0.00% | 0.0% |
| Q4 2021 | $25,000 | -51.9% | 663 | -49.6% | 0.00% | -50.0% |
| Q3 2021 | $52,000 | -3.7% | 1,316 | +8.6% | 0.00% | -33.3% |
| Q2 2021 | $54,000 | -5.3% | 1,212 | -13.6% | 0.00% | 0.0% |
| Q1 2021 | $57,000 | +62.9% | 1,403 | +67.8% | 0.00% | +50.0% |
| Q4 2020 | $35,000 | +337.5% | 836 | +170.6% | 0.00% | +100.0% |
| Q3 2020 | $8,000 | +60.0% | 309 | +66.1% | 0.00% | – |
| Q2 2020 | $5,000 | – | 186 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |